Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $14.65, but opened at $15.81. Terumo shares last traded at $15.23, with a volume of 1,310 shares.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on TRUMY. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Nomura raised Terumo from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat.com, the company has a consensus rating of “Strong Buy”.
View Our Latest Analysis on TRUMY
Terumo Price Performance
The company has a debt-to-equity ratio of 0.13, a current ratio of 2.19 and a quick ratio of 1.37. The company has a 50 day moving average price of $15.06 and a 200 day moving average price of $14.25. The firm has a market cap of $22.45 billion, a PE ratio of 21.44 and a beta of 0.77.
Terumo (OTCMKTS:TRUMY – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.13. The firm had revenue of $1.97 billion for the quarter, compared to analyst estimates of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. Sell-side analysts expect that Terumo Corp. will post 0.86 EPS for the current fiscal year.
About Terumo
Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.
The company’s products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.
Read More
- Five stocks we like better than Terumo
- Adults Are Fueling a Toy Boom—These 4 Stocks Could Cash In
- Could Quantinuum’s Breakthrough Make Its Sell-Off a Bargain?
- Wired for Upside: Why Goldman Sachs Upgraded CoreWeave’s Battered Stock
- CarMax’s Double Upgrade Could Signal a Bigger Turnaround
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
